Acute Uncomplicated Gonorrhoea Research Articles

Aztreonam: Worldwide overview of the treatment of patients with gram-negative infections

Multicenter trials were conducted to determine the safety and efficacy of aztreonam in the treatment of patients with gram-negative bacterial infections. A total of 2,821 patients were treated; 2,117 received aztreonam and 704 received control antibiotics. All patients were evaluated for safety and 1,180 of those treated with aztreonam and 428 treated with the control drugs met the criteria for efficacy evaluation. The number of patients treated with aztreonam who were evaluable for efficacy and their microbiologic response rates were: urinary tract infections, 443 (82 percent); lower respiratory tract infections, 217 (79 percent); septicemia, 63 (98 percent); skin/ skin structure infections, 136 (88 percent); intra-abdominal infections, 47 (85 percent); postpartum/gynecologic infections, 21 (100 percent); bone and joint infections, 12 (100 percent); acute uncomplicated gonorrhea, 209 (97 percent); and acute uncomplicated cystitis, 56 (84 percent). Adverse reactions were qualitatively similar to those reported for beta-lactam antibiotics, i.e., mild gastrointestinal upset, rash, eosinophilia, or transient increase in hepatic enzyme parameters. There was an apparent lack of adverse effects on kidney, inner ear, and blood coagulation system. The most frequent adverse effect was phlebitis at infusion site (2.4 percent of patients). Superinfections and colonization with new organisms occurred in 9.4 percent of aztreonam-treated patients and in 7.4 percent of control drug-treated patients; only 40 percent of patients in each group, approximately 4 percent of all patients receiving aztreonam and 3 percent of those receiving control antibiotics, required specific therapy for the superinfection. Overall, results indicated that aztreonam is a safe and effective antibiotic in the treatment of aerobic gram-negative infections, when used either as monotherapy or in combination with other antibiotics.

Treatment of Uncomplicated Gonorrhea in Women with a Single Oral Dose of Amoxicillin

Amoxicillin was used to treat acute uncomplicated gonorrhea; 89 women were given a single oral dose of either 3.0 g of amoxicillin or 2.0 g of amoxicillin plus 0.5 g of probenecid. The cervix, pharynx, and rectum of each patient were cultured, and the patients were asked to return for follow-up visits after three to five and seven to 10 days, when all three sites were again cultured. There was at least one follow-up examination on 82 of the 89 patients. The failure rate in patients denying reexposure to gonorrhea were 4.6% in those treated with the 3-g regimen and 10.5% in those receiving the 2-g regimen with probenecid. There were also three patients in each treatment group in whom the reisolations of gonococci at follow-up were felt to be due to reexposure to gonorrhea. Although 40% initially had positive rectal cultures, there were no failures at the rectal site. In contrast, two of four patients with pharyngeal gonorrhea were failures. It is concluded that the two single-dose oral regimens of amoxicillin are adequate therapy for uncomplicated genital and rectal gonorrhea in women but may not be adequate for pharyngeal gonorrhea. Amoxicillin has an antibacterial spectrum comparable to that of ampicillin [1]. The superior oral absorption of amoxicillin [2, 3] might allow oral treatment regimens for uncomplicated gonorrhea at least as effective as established single-dose oral ampicillin regimens. Possibly, the inconvenience and minor side effects of high-dose oral ampicillin regimens might be ameliorated by using lower doses of amoxicillin to achieve comparable serum levels of antibiotic. We decided to test the efficacy

Triple tetracycline ('Deteclo') as a single dose oral treatment of uncomplicated gonorrhoea in the male.

SummaryTwo hundred and sixty-nine patients suffering from acute gonococcal urethritis were treated with single oral doses (variable) of a triple tetracycline preparation (‘Deteclo’).In acute uncomplicated gonorrhoea, it was found that a single-session treatment with 1.2g. 'Deteclo' gave a failure rate of 6.2%. Side-effects were of a gastrointestinal nature and were not a serious hazard at that particular dosage. They were minimised by an antiemetic, viz. promazine hydrochloride or metaclopramide mono-hydrochloride.It would appear, therefore, that 'Deteclo' has all the advantages of any oral preparation which can be used in a single-session treatment of acute uncomplicated gonorrhoea. It should, therefore, be considered in this light as an effective, convenient, alternative treatment in uncomplicated male gonorrhoea.Because of frequent and often distressing side-effects, it was not possible to arrive at an acceptable single-session regime using 'Deteclo' in non-specific urethritis.

A Comparison between Pivampicillin, Ampicillin and Penicillin G in the Treatment of Acute Uncomplicated Gonorrhoea

In the treatment of uncomplicated gonorrhoea pivampicillin, a recently introduced ampicillin derivative with improved oral absorption, has been compared with oral ampicillin and parenteral penicillin

The treatment of acute uncomplicated gonorrhoea in the male by means of a single intramuscular injection of oily penicillin B.P.

The treatment of acute uncomplicated gonorrhoea in the male by means of a single intramuscular injection of oily penicillin B.P.